Altimmune (STU:3G0) LT-Debt-to-Total-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Altimmune LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Altimmune's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.01.

Altimmune's long-term debt to total assets ratio increased from Dec. 2023 (0.00) to Dec. 2024 (0.01). It may suggest that Altimmune is progressively becoming more dependent on debt to grow their business.

Altimmune LT-Debt-to-Total-Asset Historical Data

The historical data trend for Altimmune's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune LT-Debt-to-Total-Asset Chart

Altimmune Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Altimmune Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	0.01	0.01	0.01

Altimmune LT-Debt-to-Total-Asset Calculation

Altimmune's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	1.339	/	133.037
	=	0.01

Altimmune's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	1.339	/	133.037
	=	0.01

Altimmune (STU:3G0) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Altimmune LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Altimmune's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Altimmune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (STU:3G0) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ALT:USA ALT1:Mexico 0A4C:UK 3G0:Germany

Address

910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878

Website

https://www.altimmune.com

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Headlines

No Headlines